Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05286320 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

StatusUnknown
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 2, 2023 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2022); last known: Not Yet Recruiting
  2. Start date: Feb 1, 2023 to Mar 1, 2023v4
  3. Start date: Oct 1, 2022 to Feb 1, 2023v3
  4. Primary and study completion dates: Dec 31, 2025 to Sep 30, 2026 Start date: Mar 28, 2022 to Oct 1, 2022 · Eligibility criteria shortened, about 16 wordsv2 Show 2 more changesShow less
    • Start date: Mar 28, 2022 to Oct 1, 2022
    • Eligibility criteria shortened, about 16 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
HCC patients with PVTT (main trunk or the first-degree branch) treated with the combination of pembrolizumab (Ketruda), lenvatinib (Lenvima), and SBRT.
Trial Details
NCT Number NCT05286320
Lead Sponsor National Taiwan University Hospital
Conditions Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib, Stereotactic Body Radiotherapy
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov